ArticleFrontiers in endocrinology2025
Association between the triglyceride-glucose-waist-to-height ratio and cardiovascular disease in Chinese adults with sarcopenia or probable sarcopenia.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and external validation of a composite biomarker-based machine learning model for sarcopenia risk stratification in patients with cardiovascular disease.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sarcopenia, an age-related syndrome characterized by decreased muscle mass and performance, has been increasingly linked to high cardiovascular disease (CVD) risk. In this study, sarcopenia and probable sarcopenia were diagnosed according to the Asian Working Group for Sarcopenia (AWGS) 2019 criteria. However, specific biomarkers underlying this association, such as the triglyceride-glucose-waist-to-height ratio (TyG-WHtR), remain unclear. Methods: A cohort of 2,521 adults ≥45 years with sarcopenia or probable sarcopenia (2011-2020) were stratified by TyG-WHtR tertiles: T1 (≤4.30), T2 (4.30-5.01), and T3 (>5.01). To quantify the predictive utility of TyG-WHtR for CVD, methods such as Cox proportional hazards models, restricted cubic splines, and threshold regression analyses were utilized. Results: Over 7.3 years (median), incident CVD was documented in 727 individuals, including 258 patients who had a stroke and 560 patients who had heart diseases. Adjusted Cox models revealed that higher TyG-WHtR was independently associated with increased CVD risk: each one-unit increase corresponded to an 11% higher CVD risk (HR 1.11, 95% CI 1.01-1.22) and a 25% higher stroke risk (HR 1.25, 95% CI 1.06-1.47). Tertile analyses showed graded associations, with individuals in the highest tertile (T3) having a 51% higher risk of CVD, 90% higher risk of stroke, and 42% higher risk of heart diseases compared with T1. Threshold regression revealed a nonlinear relationship: when TyG-WHtR exceeded 3.76, CVD risk rose markedly (HR 1.22, Discussion: In individuals with sarcopenia or probable sarcopenia, high TyG-WHtR is independently associated with higher CVD risk, demonstrating a distinct threshold effect. TyG-WHtR may be a valuable marker for predicting CVD risk in this population, thus enabling early cardiovascular risk stratification and personalized interventions for this group. However, these findings still require further validation through large-scale studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.